How to Write a Pharma Programmatic Brief That Partners Can Execute
A pharma programmatic brief structure: objective, audience, constraints, measurement, and approval gates, plus ambiguity checks before it goes to partners.
The short answer
A programmatic brief tells partners what the brand needs, within what limits, and how success will be judged. Weak briefs lead to plans that answer the wrong question, repeated revisions, and arguments after launch about what was agreed. A good brief is short, specific, and hard to misread.
The brief structure
1. Business context
Two or three sentences on the brand situation: launch, growth, defense, or new indication. What has changed since the last plan?
2. Objective
One primary objective stated as a behavior change, with a measurable outcome. "Increase new-to-brand prescriptions among target prescribers" is better than "drive awareness and engagement."
3. Audience
- Who: target list or audience definition, with source and date.
- Priority segments.
- Exclusions. See exclusion rules.
4. Budget and timing
- Total budget and flighting.
- Any committed or conditional portions.
- Key dates: launches, conferences, label updates.
5. Constraints
- Regulatory: approved claims, required risk information, format limits. The FDA's guidance on presenting risk information affects format choices.
- Privacy: data sources and uses approved.
- Operational: creative refresh timelines, review windows.
- Partner restrictions: required or excluded partners.
6. Measurement
- Primary KPI and how it will be measured.
- Secondary KPIs.
- Measurement partner and study design. See the measurement design guide.
- Decision the measurement will inform.
7. Deliverables and approval gates
What partners should return, by when, and who approves each stage.
Ambiguity checks
Before sending, test the brief with these questions:
| Check | Question |
|---|---|
| Single objective | Could two partners read the objective and pursue different goals? |
| Measurable | Can the primary KPI be measured with the data available? |
| Audience source | Is it clear which list or segment to use? |
| Constraints complete | Are review timelines and format limits stated? |
| Decision owner | Is it clear who approves the plan? |
If any answer is unclear, fix it before partners start planning.
Common brief mistakes
- Multiple equal objectives. Partners optimize for whichever is easiest.
- Missing exclusions. Discovered after launch, when fixing them is harder.
- Measurement as an afterthought. Design choices, like holdouts, must be made before planning.
- No mention of review timelines. Plans assume creative agility the brand does not have.
Connect the brief to the investment thesis
If the brand has a media investment thesis, the brief should reflect it. The thesis explains why; the brief explains what and how.
Practical takeaway
Keep the brief to two pages. Run the five ambiguity checks with a colleague who was not involved in drafting it. Their questions show where partners will get confused.
Sources
- FDA, Presenting Risk Information in Prescription Drug and Medical Device Promotion
- FDA Office of Prescription Drug Promotion
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.